オハイオにおける膠芽腫の臨床試験
オハイオ内の拠点で、膠芽腫に関する23件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05432804A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- University Hospitals Cleveland Medical Center*, Cleveland
- Cleveland Clinic, Cleveland
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT03970447Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- Neurological Institute Brain Tumor Centre Taussig Cancer Cente, Cleveland
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05902169Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Cleveland Clinic Taussig Cancer Center, Cleveland
- Ohio State University, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07326566Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- The Ohio State University, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07195591Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
- Case Western Reserve University, Cleveland
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/10更新 · NCT07452458hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT05052957Targeted Pediatric High-Grade Glioma Therapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中観察研究
12 Months – 39 Years · 全性別 · 2026/09/08更新 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中第2相
12歳〜39歳 · 全性別 · 2026/09/01更新 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Cleveland Clinic, Cleveland
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/06更新 · NCT05565118A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07003542Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
- Ohio State University Medical Center, Columbus
被験者募集中
18歳〜85歳 · 全性別 · 2026/07/21更新 · NCT06910306Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
- Ohio State University, Columbus
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/07/17更新 · NCT07225621DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/01更新 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中早期第1相健康なボランティア歓迎
1歳〜21歳 · 全性別 · 2026/06/29更新 · NCT06333899Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
- Ohio State University Hospital, Columbus
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/06/12更新 · NCT07346144Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/05/29更新 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06810544Sacituzumab Govitecan in Recurrent Glioblastoma
- Cleveland Clinic Taussig Cancer Center, Cleveland
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/30更新 · NCT04559230SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- The Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2025/06/25更新 · NCT05879367ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。